To Get more Insights,  Request A Free Sample 

Analysis of Top 3 New Horizons of Advanced Therapeutics Protein Markets:

• Plasma Protein Therapeutics Market.

The future of the plasma protein therapeutics market has been characterized by a tremendous growth in the supply chain of raw materials and high-end clinical demand. There is an increased rapid growth of the network of plasma collection centers to address the therapeutic needs. Other key collectors such as CSL Plasma and Octapharma are growing in the U.S. alone, with CSL exceeding 300 centers. This facility expansion is essential to facilitate the high demand of the plasma-derived medicines. Indicatively, one patient with hemophilia A could need a year of treatment in which 1,200 individual donations are needed to provide him with plasma. Moreover, the market can be supported with the constant inflow of product approvals and the extended indications as the companies are constantly moving forward with the therapies of immunology, neurology and coagulation disorders through the channel of regulation.

• Recombinant Plasma protein Therapeutics Market.

The market of recombinant plasma protein therapeutics is gaining pace of innovations that are propelled by the high pipeline and strategic investments in R&D. In March 2024, FDA granted IXINITY, a recombinant coagulation Factor IX, a broader label indication, as IXINITY can now be used on pediatric patients, enabling it to expand its market. Hemophilia A and B pipeline is a highly active one, and over 10 companies work on next-generation therapies. In July 2024, Pfizer announced positive results of its Phase 3 AFFINE trial of its hemophilia A gene therapy, which heralded a possible change in paradigms of treatment. Another first-in-class prophylaxis, Hympavzi, against hemophilia A and B, was also approved in October 2024 by the FDA. It is based on the basis of these developments that there is a distinct movement towards more beneficial and convenient non-plasma-derived treatment with the help of substantial R&D investments.

• Therapeutic Proteins and Oral Vaccines Market.

The oral vaccines and Protein therapeutics market is heading towards needle-free solutions where both clinical and financial milestones have been recorded. Vaxart has been a leading force and began the 10,000-part participant of its Phase 2b trial of an oral COVID-19 vaccine in May 2025. This is a massive trial which directly compares its oral candidate to a workable mRNA vaccine, the initial move to potential approval. Investments in such innovation are robust, and in June 2024, Plantform Corp. was given government funding to create a swine virus oral vaccine, which has shown a possible broader use of the technology. Also, companies are already patents on intellectual property, with many patents being registered on oral protein delivery platforms, which are needed to safeguard therapeutic proteins on their way through the digestive system.

Protein Therapeutics Market Future Growth Frontiers.

• Cell-Free Protein Synthesis (CFPS) is reducing times to development. CFPS systems are a groundbreaking technology in the production of proteins using non-living cells. One way minimizes the development and manufacturing periods drastically. There is emerging opportunities of developing on-demand therapeutic proteins, screening drug candidates in a short period and making complex proteins that are challenging to express using conventional cell lines. This technology provides increased speed of iteration and production to establish a major competitive advantage in the protein therapeutics competitive market that is fast moving.
• Targeted Protein Degradation (TPD) opens up unreachable targets. TPD technologies, such as proteolysis-targeting chimeras (PROTACs) are a breakthrough in proteolysis-targeting. Rather than simply inhibiting the activity of a protein, these molecules label the unwanted proteins to be fully degraded by the cell disposal mechanisms in the Protein therapeutics market. One great mechanism unlocks the chances of attacking the 85% of the proteome that was previously thought to be undruggable. The companies that invest in TPD will be able to respond to an extremely large new frontier of diseases, developing new treatment approaches that may be even more effective and enduring.

Cell and Gene Therapy Boom Generates Huge Ancillary Protein Demand.

The cell and gene therapies (CGT) are expanding tremendously and this is giving rise to a large second need of highly specialized proteins in the Protein therapeutics market. As an example, as of early 2024, there are over 420 protein-based vectors gene therapies undergoing clinical trials, all of which use protein-based vectors to deliver the gene therapy. These vectors, in particular the 15 adeno-associated virus (AAV) serotypes most widely used, cannot be produced without huge amounts of particular viral proteins. Also, many of the new therapies are novel engineered proteins, such as CRISPR-Cas9, which drive the revolution of gene-editing. Scientists have already designed more than 2,200 variants of Cas9 protein to enhance specificity and efficiency.

This is leading to the overall CGT manufacturing ecosystem scaling up, which is specifically driving the protein therapeutics market directly. To satisfy this demand, at least 12 new CGT manufacturing plants started being built around the world in 2024. By 2025, the FDA expects to receive over 200 additional new cell and gene therapy applications every year. The need of GMP-grade enzymes, viral capsid proteins and growth factors is huge with 7 approved CAR-T therapies in the U.S and more than 950 active clinical trials of regenerative medicines ongoing in 2024. Delivery systems also require the presence of proteins, and as of 2024, more than 300 patents were registered on lipid nanoparticle protein constituents.

New Market Competitive Demand Dynamics have been created by Biosimilar Wave

The growing biosimilar market is essentially altering the market forces of demand in the protein therapeutics market. There is growing competition, which is clearly manifested in the introduction of 11 Humira biosimilars into the American market up to 2024. This is not only a cost saving exercise but also an initiative that initiates innovation. In order to differentiate, firms are coming up with so-called biobetters, which are better to deliver or work. More than 60 biobetters are in Phase 3 clinical trials all over the world were found as of 2025. The new protein engineering and sophisticated formulation skills are the result of this trend.

Furthermore, the control channel is becoming even more specific, which is fueling the market more. In early 2024, the EMA granted 6 biosimilars to Stelara, which is yet another significant biologic with a growth of competition. The FDA has awarded 5 biosimilar products the designation of interchangeable in the U.S., which is a designation that enhances pharmacy-level substitution and penetration. This trend is both global, and according to the forecasts, by the end of 2025, more than 80 additional biosimilar approvals are expected in China. As a result of this competitive pressure, more than 45 patent settlement agreements have been made between originator and biosimilar companies in 2024 with this influencing the timing and manner of entry into the market and maintaining a dynamic demand cycle.

Segmental Analysis 

Targeted Therapy Revolution Heralded by Monoclonal Antibodies.

The segment of mono-clonal antibodies, with its dominant market share of 51% is an example of a fundamental change towards precision medicine. Overall, Monoclonal antibodies take up 13 out of 16 new biologics granted approval by the FDA in 2024, which highlights how research and development in the field is rife; with the approval of donanemab in Alzheimer in July 2024, the field of challenging neurological diseases has received a substantial entry. The robust pipeline within the protein therapeutics market is further highlighted by the 30 investigational antibodies under regulatory review at the end of 2024. momentum is sustained by constant innovation in complex antibody formats.

• The world has received 21 new antibody-based therapeutics during 2024.
• One of the trends is the emergence of superior formats, with 6 bispecific antibodies being approved in 2024.
• The market is gradually growing via accessibility, where 6 denosumab biosimilars have been approved by March 2025.

The clinical activity and regulatory success, in themselves, are overwhelming enough to consolidate the dominance of the segment. The green light that FDA has given on an extra six biologics before mid 2025 indicates no deceleration of the trend. Moreover, the fact that 9 new biologics have received first-in-class therapy status in 2024 is an indication of revolutionary changes that will help meet medical needs that were not met. This commercial success is also palpable, as the US sales on the products of denosumab are almost 5 billion dollars in 2024. A combination of a packed pipeline, expanding applications, and strong market uptake ensures the monoclonal antibody segment will continue to lead the protein therapeutics market for the foreseeable future.

The Unprecedented Market Demand is fueled by Metabolic Disorders.

The impressive market share of the metabolic disorders segment standing at 33% is a direct consequence of the worldwide diabetes and obesity epidemic. Drugs that contain proteins have now become vital in control of chronic illnesses that afflict hundreds of millions of individuals. The 8,412,584 GLP-1 RA prescriptions written in 2018-2024 represent the demand that covers more than 1.8 million patients. The use of newer anti-obesity medications is especially notable, as the number of prescriptions of these medications is skyrocketing to 1.5 million every month in February 2024. Such figures reflect the immense patient population and the clinical success of treatments within the protein therapeutics market.

• Chronic disease is one of the key health challenges in the world with 41 million deaths every year.
• Among them, 2.0 million deaths every year are directly caused by diabetes and complications.
• More than 70 lysosomal storage disorders are present in the treatment landscape of rare metabolic disorders.

The high-volume chronic disease and the high value rare disease treatments are drivers of the growth of this segment. Already in 2023 in the first half year, almost 230,000 patients with obesity or overweight have begun taking a GLP-1 RA, as well as more than 180,000 new patients with type 2 diabetes. Their success as blockbuster drugs is secured by the potent impact of these treatments, including semaglutide and tirzepatide that sold 670,000 prescriptions in one month. The consistent and long-term nature of these treatments ensures a sustained revenue stream, reinforcing the metabolic disorders segment as the anchor of the protein therapeutics market.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America: The Unchallenged Leader of Biologic Innovation

North America, holding over 42% of the global market share, unequivocally leads the protein therapeutics market. Its leadership is anchored on the basis of an innovative research and well-structured administrative framework. As of 2024, Biologics License Applications (BLAs) could be submitted using the advanced format eCTD v4.0, which simplified the submissions. The number of early-stage innovations is overwhelming, and the Center of Biologics Evaluation and Research (CBER) of the FDA has thousands of ongoing Investigational New Drug (IND) programs on biologics. The dedication of the U.S. government is also reflected by large-scale national institutes of health (NIH) support of protein engineering and supporting biotechnologies.

The inflow of venture capital is not yet stopping in the region since the biotechs based in the United States always get investments worth multi-billion dollars every year. The result of this financial firepower is a well-developed ecosystem that has resulted in biotech patents being registered at the USPTO in large numbers per year. Canada is another country which is making significant contribution and it is delivering its own biotech venture capital scene, and there is a significant number of clinical trials. The FDA's final rule in February 2024, clarifying the use of Drug Master Files for biologics, further solidified regulatory predictability, reinforcing the region's position as the primary engine of the global protein therapeutics market.

Europe Champions Integrative Research and Development Regulatory Science.

Europe stands as a formidable force in the protein therapeutics market, driven by collaborative research initiatives and a sophisticated, harmonized regulatory system. The Horizon Europe program EUR95.5 billion is one of them and provides many funding opportunities in 2024 and 2025 in the area of alternative protein research and biomanufacturing. This investment creates a deep pipeline of new therapy. The high number of scientific advice requests by the European Medicines Agency (EMA) of biologics examples is a sign of regulatory leadership as it assists developers at early stages. 

The Medicines and healthcare products regulatory agency (MHRA) in the UK is progressing its biosimilar licensing guidance at a national level, which could speed up the process of biosimilars gaining market access. This efficiency was evident with four ustekinumab biosimilars having already been approved by the UK as of September 2024. In Germany, a significant center of clinical research activities, there will be a significant number of ongoing monoclonal antibody clinical trials in 2024.

Asia Pacific: A Bio manufacturing and Biosimilar Superpower.

The Asia Pacific region is rapidly ascending as a critical hub in the protein therapeutics market, defined by its massive manufacturing scale and dynamic biosimilar development. One of its driving forces is China, through its National Medical Products Administration (NMPA) who approved 83 new drugs in 2024, many being biologics. In China, the Center for Drug Evaluation (CDE) received 2,447 biologic products registration applications in 2024, of which 1,188 were INDs and 254 New Drug Applications (NDAs) for biologic products. 

To back this volume, the NMPA announced a pilot plan in October 2024 to soften end-to-end manufacturing regulations, increasing the importance of CDMOs in the Protein therapeutics market. India has firmly established itself as a country of choice in biosimilar clinical trials as it has a ready pool of skilled labor and economies of scale to back any submission to FDA and EMA. The regulatory authority of the country, the CDSCO is busy revising its biosimilar regulations to be in line with the international standards. South Korea, meanwhile, is steadily increasing its large biomanufacturing capacity, both in the domestic and international markets.

High-Value Deals and Investments Signal Intense Confidence in Protein Therapeutics Market

• Novo Holdings Acquires Catalent ($16.5B Feb 2024): Using the largest deal of the year, Novo Holdings acquired CDMO giant Catalent with a view to massively increase the production capacity of its parent company Novo Nordisk.
• Vertex Pharmaceuticals Acquires Alpine Immune Sciences ($4.9B April 2024): The acquisition allowed Vertex to acquire the lead protein-based immunotherapy candidate, povetacicept, to treat autoimmune kidney disorders.
• Gilead Sciences Acquires CymaBay Therapeutics ($4.3B Feb 2024): With this acquisition Gilead gained access to the lead investigational product of CymaBay in primary biliary cholangitis to add to its liver disease portfolio.
• Xaira Therapeutics Securities Funding (1B+  Apr 2024): The AI-oriented biotech raised more than 1 billion dollars with the help of top venture capital firms to create AI-powered drug discovery and development platforms.
• AstraZeneca Acquires Fusion Pharmaceuticals (2.4B Mar 2024): AstraZeneca has bolstered its oncology pipeline with the acquisition of Fusion and its next-generation platform of radioconjugates to deliver precision cancer treatment.
• Johnson & Johnson Buys Ambrx Biopharma ($2B Jan 2024): J&J has acquired Ambrx to use its specialty platform to develop advanced and highly targeted antibody-drug conjugates (ADCs) to treat cancer.
• Novartis sells Mariana Oncology ($1.75B May 2024): Novartis strengthened its radioligand therapy portfolio, paying a upfront fee of 1 billion with possible milestones, to acquire the preclinical-stage cancer therapy developer.
• Mirador Therapeutics Starts with Funding ($400M Mar 2024): The precision medicine startup launched with an enormous Series A round to create therapies to inflammatory and fibrotic diseases based on its proprietary data platform.
• Genmab Acquires ProfoundBio ($1.8B Apr 2024): Genmab acquired ProfoundBio in a cash deal to acquire three clinical-stage ADC candidates and augment its next generation oncology pipeline.
• Candid Therapeutics Founding ($370M Sep 2024): The startup biotech company was founded on a huge capital investment to develop T-cell engager antibodies that are specifically tailored to treat inflammatory

Top Companies in the Protein Therapeutics Market

• Bayer AG
• Bristol-Myers Squibb
• Daiichi Sankyo Company
• Abbott
• Sanofi
• Thermo Fisher Scientific Inc.
• Genzyme Corporation
• AbbVie Inc.
• Leadiant Biosciences
• Takeda Pharmaceutical Company Limited
• Other Prominent Players

Market Segmentation Overview

By Product

• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Erythropoietin
• Interferon
• Human Growth Hormone
• Follicle Stimulating Hormone

By Applications

• Metabolic Disorders
• Immunologic Disorders
• Hematological Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders

By Region

• North America
  • The US
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America